Gizem Şenyazar

Gizem Şenyazar

Auto-generated profile, based on publicly available information

Gizem Şenyazar

Department of Pediatric Endocrinology , 63990 Ankara University Faculty of Medicine , Ankara , Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2023 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
SÇSirmen Kızılcan Çeti̇n
Sirmen Kızılcan Çeti̇n
ZAZehra Aycan
Zehra Aycan
EÖElif Özsu
Elif Özsu
ZSZeynep Siklar
Zeynep Siklar
ACAyşegül Ceran
Ayşegül Ceran
MBMerih Berberoğlu
Merih Berberoğlu
Abnormal uterine bleeding (AUB) is adolescent girls' most common gynecologic complaint. This study aimed to determine the diagnostic and management differences between those with/without heavy menstrual bleeding. We collected retrospective data such as follow-up, final control, and treatment regimen of adolescents aged 10-19 with the diagnosis of AUB. We excluded adolescents with known bleeding disorders at admission. We classified all subjects according to the level of anemia. Group 1 consisted of subjects with heavy bleeding (Hb10 g/dl) presented in Group 2. Admission and follow-up characteristics between the two groups were compared. In this study, we included 79 adolescent girls with a mean age was 14.3±1.8 years. 85% of all had a menstrual irregularity in the first two years after menarche. Anovulation was observed in 80%. 95% of group 1 had irregular bleeding in the two years (p<0.01). In all subjects, while 13 girls (16%) were diagnosed with PCOS, two adolescents (2%) had structural anomalies. No adolescents had hypothyroidism or hyperprolactinemia. Three (10.7%) were diagnosed with Factor 7 deficiency. Nineteen girls had MTHFR mutation. None had venous thromboembolism during at least six month-follow-up-period. This study showed that 85% of AUB had occurred in the first two years. We found the frequency of hematological disease (Factor 7 deficiency) 10.7%. The frequency of MTHFR mutation was 50%. We thought this did not increase the risk of bleeding/thrombosis. Its routine evaluation was not necessarily due to the similarity in population frequency.

26 March 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
SÇSirmen Kızılcan Çeti̇n
Sirmen Kızılcan Çeti̇n
EÖElif Özsu
Elif Özsu
ZSZeynep Siklar
Zeynep Siklar
HCHasan Fatih Cakmakli
Hasan Fatih Cakmakli
GŞGizem Şenyazar
Gizem Şenyazar
MBMerih Berberoğlu
Merih Berberoğlu
MIRAGE syndrome is a rare multisystemic disorder characterized by various manifestations, such as myelodysplasia, susceptibility to infections, growth retardation, adrenal hypoplasia, genital anomalies, and enteropathy. In the literature, there have been rare cases of dysautonomia. We present a 6.5-year-old girl, who was first admitted to our department with short stature. On follow up, she exhibited multiple endocrinological issues, including transient hypothyroidism, primary hypoparathyroidism and dysautonomia, along with multisystem involvement. Further investigations revealed recurrent moniliasis, low IgM levels, and transient monosomy 7 in the bone marrow. Whole exome sequencing revealed a heterozygous pathogenic variant of SAMD9 (c.2159del; p.Asn720ThrfsTer35). Additional complications observed during follow-up included medullary nephrocalcinosis, hypomagnesemia, hypermagnesiuria, hypophosphatemia, decreased glomerular filtration rate, and nephrotic proteinuria. The patient also developed hyperglycemia, which was managed with low-dose insulin. This case highlights the diagnostic challenges and the diverse phenotypic presentation observed in MIRAGE syndrome.

11 August 2025 in Endocrine
Verified
Journal Article
Closed access
SGSevinc Odabasi Gunes
Sevinc Odabasi Gunes
MSMerve Sakar
Merve Sakar
NSNursel Muratoglu Sahin
Nursel Muratoglu Sahin
GKGulay Karaguzel
Gulay Karaguzel
ECEmine Ayca Cimbek
Emine Ayca Cimbek
SÇSemra Çağlar Çetinkaya
Semra Çağlar Çetinkaya

2 July 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
EŞEmine Kübra Şen
Emine Kübra Şen
MBMerih Berberoğlu
Merih Berberoğlu
GŞGizem Şenyazar
Gizem Şenyazar
SÇSirmen Kızılcan Çeti̇n
Sirmen Kızılcan Çeti̇n
ACAyşegül Ceran
Ayşegül Ceran
ZSZeynep Siklar
Zeynep Siklar
Objective: Secondary osteoporosis is a condition when the underlying disease or its treatment causes the bone mass to decrease and the bone structure to deteriorate, increasing the risk of fracture. The importance of diagnosis and treatment during childhood and adolescence is due to the long-term negative effects. In this study, our objectives were to determine the diagnostic findings, treatment efficacy, and follow-up characteristics of children with secondary osteoporosis. Methods: Patients diagnosed with secondary osteoporosis between January 2000 and January 2021 were included. The research was a cross-sectional and descriptive study. Study participants had to be under 18 years of age when the primary underlying disease was diagnosed and had received treatment for secondary osteoporosis. Patient data were collected from patient files. Statistical analysis was performed using Statistical Package for the Social Sciences, version 20.0 (IBM Corp, Armonk, NY, USA). Results: Sixty-one patients (28 female; 45.9%) were evaluated. The most common underlying primary diseases were inflammatory diseases (57.7%), neuromuscular diseases (26.2%), immunodeficiency (13.1%), acute lymphoblastic leukemia (8.2%), metabolic diseases (8.2%), solid organ transplantation (8.2%), bone marrow transplantation (6.6%) and epilepsy (6.6%). The mean +/- standard deviation chronological age when secondary osteoporosis was diagnosed was 11.89 +/- 4.88 years. Patients were evaluated for osteoporosis at a mean of 6.39 +/- 5.13 years after the onset of the underlying primary chronic diseases. Most (78.7%) had a history of one or more chronic drug use, including systemic steroids (59%), chemotherapeutics (23%), immunomodulatory drugs (19.7%), antiepileptic drugs (8.2%), inhaled steroids (4.9%), intravenous immunoglobulin (1.6%), and antituberculosis drugs 1.6%.Bone pain was detected in 49.2%. All patients had vertebral fractures before treatment. Bisphosphonate treatment was given to 45 (73.8%). There was a significant increase in mean bone mineral density (BMD) and bone mineral content six months after treatment (both p<0.001). There was a significant increase in BMD Z-score values for chronological and height age (both p<0.001). Overall mean BMD values increased by 31.15% with treatment. Following bisphosphonate treatment, there was a significant reduction in both fracture number and bone pain (p<0.01). Similar benefits from bisphosphonate treatment were evident in those who did or did not receive steroid treatment. Conclusion: Secondary osteoporosis is a condition that is influenced by many factors, such as the primary disease causing osteoporosis and chronic medication use, especially steroids. If left untreated, osteoporosis may lead to clinically important morbidity (bone pain, fractures, immobilization) and reduced linear growth of bone. When used to treat childhood secondary osteoporosis, bisphosphonates significantly improve BMD and reduced fracture risk.

11 November 2025 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SASema Nilay Abseyi
Sema Nilay Abseyi
SKSeda Erişen Karaca
Seda Erişen Karaca
ZSZeynep Siklar
Zeynep Siklar
GŞGizem Şenyazar
Gizem Şenyazar
SÇSirmen Kızılcan Çeti̇n
Sirmen Kızılcan Çeti̇n
MBMerih Berberoğlu
Merih Berberoğlu
Objectives: Nonclassical congenital adrenal hyperplasia (NCCAH) is a mild form of 21-hydroxylase deficiency that can lead to premature pubarche, rapid growth, and reduced final height. However, data on pubertal progression and final height outcomes remain variable. Methods: This retrospective study evaluated 27 patients (20 females, seven males) with genetically confirmed NCCAH, followed until final adult height at a single tertiary center between 2000 and 2020. Clinical, hormonal, and genetic parameters were assessed. Patients were grouped according to CYP21A2 mutation status: Group 1 consisted of patients with the c.844G>T (p.Val282Leu) homozygous mutation, Group 2 consisted of patients with the c.844G>T (p.Val282Leu) compound heterozygous mutation, and Group 3 consisted of patients with other mutations. Final height outcomes and pubertal characteristics were analyzed, and predictors of growth and factors affecting pubertal onset were examined using linear regression. Results: The mean age at diagnosis was 8.8 ± 3.2 years. Central precocious puberty (CPP) and rapidly progressive puberty were observed in a total of 9 cases (at presentation and during follow-up). Seven cases used GnRH analogs. Mean final adult height (FAH) SDS was −0.33 ± 0.98, with no significant differences across mutation groups. Pubertal height SDS and height SDS at diagnosis were strongly correlated with FAH SDS (p=0.0001 and p=0.0009, respectively). Although the mean pubertal onset age did not differ significantly across genotypes, menarche was significantly later in the compound heterozygous group (p=0.006). No significant relationship was found between BA/CA, mutation group, and early puberty with either FAH SDS or FAH-predicted adult height (PAH) SDS. Conclusions: Final height in NCCAH is primarily influenced by height at diagnosis, pubertal height SDS, and pubertal growth dynamics, rather than genotype or age at presentation. Regular auxological monitoring, timely recognition of pubertal changes, and individualized treatment decisions are critical for optimizing adult height outcomes.

30 June 2026 in Ankara Üniversitesi Tıp Fakültesi Mecmuası
Verified
Journal Article
Closed access
SÇSirmen Kızılcan Çeti̇n
Sirmen Kızılcan Çeti̇n
ZSZeynep Siklar
Zeynep Siklar
EÖElif Özsu
Elif Özsu
ZAZehra Aycan
Zehra Aycan
ACAysegul Ceran
Aysegul Ceran
MBMerih Berberoğlu
Merih Berberoğlu
Introduction: Adrenal insufficiency is a life-threatening endocrine disorder resulting from impaired cortisol production. It develops due to dysfunction of either the adrenal glands or the hypothalamic–pituitary axis. In children, the etiology and clinical manifestations vary widely, and delays in diagnosis and treatment can lead to significant morbidity. Objective: This study aimed to evaluate the clinical characteristics, etiological distribution, and treatment management of children diagnosed with primary adrenal insufficiency (PAI) and central adrenal insufficiency (CAI), excluding those with congenital adrenal hyperplasia (CAH). Methods: A retrospective analysis was conducted on 56 patients aged 0–18 years with PAI and CAI, followed by our Pediatric Endocrinology Department. Patients with CAH, secondary adrenal insufficiency due to steroid use, adrenal insufficiency from trauma, infections, or incomplete data were excluded. Data on clinical presentation, laboratory results, genetic assessments, and treatment were evaluated. Results: Of the 56 patients (28 males, 28 females), 75% (n=42) had CAI, and 25% (n=14) had PAI. Common etiologies in CAI included craniopharyngioma (n=21), while ACTH resistance (n=6) and APECED (n=5) were prevalent in PAI. The mean age at presentation was 6.99 ± 5.81 years, with PAI patients presenting at a younger median age (3.46 years) compared to CAI patients (6.83 years, p=0.11). Due to the predominance of craniopharyngioma patients, CAI patients had shorter stature (-1.03 ± 1.3 SD, p=0.01) and higher BMI SD scores (0.86 ± 1.72, p=0.007) than PAI patients. PAI patients exhibited higher baseline cortisol levels (7.22 ± 4.73 mcg/dL, p=0.01) and required higher initial hydrocortisone doses (20.88 ± 22.6 mg/m²/day) than CAI patients (11.49 ± 3.79 mg/m²/day, p=0.002). Conclusion: PAI patients presented younger and required higher hydrocortisone doses than CAI patients despite having higher baseline cortisol levels. Fatigue and hypoglycemia were frequent symptoms in PAI, while CAI presentations varied based on etiology.